Peritoneal Cancer – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Peritoneal Cancer – Pipeline Review, H1 2017’, provides an overview of the Peritoneal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peritoneal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer

The report reviews pipeline therapeutics for Peritoneal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Peritoneal Cancer therapeutics and enlists all their major and minor projects

The report assesses Peritoneal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Peritoneal Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Peritoneal Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Peritoneal Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3-V Biosciences Inc

AbbVie Inc

Adaptimmune Therapeutics Plc

Aduro BioTech Inc

Advenchen Laboratories LLC

Altor BioScience Corp

Amgen Inc

Arrien Pharmaceuticals LLC

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

AVEO Pharmaceuticals Inc

Bayer AG

BeiGene Ltd

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

Celgene Corp

Celldex Therapeutics Inc

Celsion Corp

CerRx Inc

Clovis Oncology Inc

Critical Outcome Technologies Inc

Dr. Reddy's Laboratories Ltd

Eisai Co Ltd

Eli Lilly and Company

EpiThany Inc

Esperance Pharmaceuticals Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Galena Biopharma Inc

Gene Techno Science Co Ltd

Genelux Corp

Genentech Inc

Genor BioPharma Co Ltd

Glycotope GmbH

Gradalis Inc

Hemispherx Biopharma Inc

ImmunoGen Inc

Immunovaccine Inc

Incyte Corp

Innate Pharma SA

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Juno Therapeutics Inc

Lidds AB

Mabion SA

MabVax Therapeutics Holdings Inc

Mateon Therapeutics Inc

MedImmune LLC

Medivir AB

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

MolMed SpA

Mycenax Biotech Inc

NewLink Genetics Corp

Novartis AG

Novogen Ltd

Oasmia Pharmaceutical AB

OBI Pharma Inc

Oncobiologics Inc

Oncolix Inc

Oncolytics Biotech Inc

OncoMed Pharmaceuticals Inc

Ono Pharmaceutical Co Ltd

Oxford BioMedica Plc

Pfizer Inc

Pharma Mar SA

Polaris Pharmaceuticals Inc

PsiOxus Therapeutics Ltd

Richter Gedeon Nyrt

Samyang Holdings Corp

Sanofi

Sanofi Pasteur SA

Sotio AS

Syndax Pharmaceuticals Inc

TapImmune Inc

Tyrogenex Inc

Vascular Biogenics Ltd

VentiRx Pharmaceuticals Inc

Verastem Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Peritoneal Cancer - Overview 7

Peritoneal Cancer - Therapeutics Development 8

Peritoneal Cancer - Therapeutics Assessment 24

Peritoneal Cancer - Companies Involved in Therapeutics Development 40

Peritoneal Cancer - Drug Profiles 82

Peritoneal Cancer - Dormant Projects 734

Peritoneal Cancer - Discontinued Products 737

Peritoneal Cancer - Product Development Milestones 738

Appendix 745

List of Tables

List of Tables

Number of Products under Development for Peritoneal Cancer, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Peritoneal Cancer – Pipeline by 3-V Biosciences Inc, H1 2017

Peritoneal Cancer – Pipeline by AbbVie Inc, H1 2017

Peritoneal Cancer – Pipeline by Adaptimmune Therapeutics Plc, H1 2017

Peritoneal Cancer – Pipeline by Aduro BioTech Inc, H1 2017

Peritoneal Cancer – Pipeline by Advenchen Laboratories LLC, H1 2017

Peritoneal Cancer – Pipeline by Altor BioScience Corp, H1 2017

Peritoneal Cancer – Pipeline by Amgen Inc, H1 2017

Peritoneal Cancer – Pipeline by Arrien Pharmaceuticals LLC, H1 2017

Peritoneal Cancer – Pipeline by Astellas Pharma Inc, H1 2017

Peritoneal Cancer – Pipeline by Astex Pharmaceuticals Inc, H1 2017

Peritoneal Cancer – Pipeline by AstraZeneca Plc, H1 2017

Peritoneal Cancer – Pipeline by Atara Biotherapeutics Inc, H1 2017

Peritoneal Cancer – Pipeline by AVEO Pharmaceuticals Inc, H1 2017

Peritoneal Cancer – Pipeline by Bayer AG, H1 2017

Peritoneal Cancer – Pipeline by BeiGene Ltd, H1 2017

Peritoneal Cancer – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Peritoneal Cancer – Pipeline by Boston Biomedical Inc, H1 2017

Peritoneal Cancer – Pipeline by Bristol-Myers Squibb Company, H1 2017

Peritoneal Cancer – Pipeline by Celgene Corp, H1 2017

Peritoneal Cancer – Pipeline by Celldex Therapeutics Inc, H1 2017

Peritoneal Cancer – Pipeline by Celsion Corp, H1 2017

Peritoneal Cancer – Pipeline by CerRx Inc, H1 2017

Peritoneal Cancer – Pipeline by Clovis Oncology Inc, H1 2017

Peritoneal Cancer – Pipeline by Critical Outcome Technologies Inc, H1 2017

Peritoneal Cancer – Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017

Peritoneal Cancer – Pipeline by Eisai Co Ltd, H1 2017

Peritoneal Cancer – Pipeline by Eli Lilly and Company, H1 2017

Peritoneal Cancer – Pipeline by EpiThany Inc, H1 2017

Peritoneal Cancer – Pipeline by Esperance Pharmaceuticals Inc, H1 2017

Peritoneal Cancer – Pipeline by Exelixis Inc, H1 2017

Peritoneal Cancer – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Peritoneal Cancer – Pipeline by Galena Biopharma Inc, H1 2017

Peritoneal Cancer – Pipeline by Gene Techno Science Co Ltd, H1 2017

Peritoneal Cancer – Pipeline by Genelux Corp, H1 2017

Peritoneal Cancer – Pipeline by Genentech Inc, H1 2017

Peritoneal Cancer – Pipeline by Genor BioPharma Co Ltd, H1 2017

Peritoneal Cancer – Pipeline by Glycotope GmbH, H1 2017

Peritoneal Cancer – Pipeline by Gradalis Inc, H1 2017

Peritoneal Cancer – Pipeline by Hemispherx Biopharma Inc, H1 2017

Peritoneal Cancer – Pipeline by ImmunoGen Inc, H1 2017

Peritoneal Cancer – Pipeline by Immunovaccine Inc, H1 2017

Peritoneal Cancer – Pipeline by Incyte Corp, H1 2017

Peritoneal Cancer – Pipeline by Innate Pharma SA, H1 2017

Peritoneal Cancer – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017

Peritoneal Cancer – Pipeline by Johnson & Johnson, H1 2017

Peritoneal Cancer – Pipeline by Juno Therapeutics Inc, H1 2017

Peritoneal Cancer – Pipeline by Lidds AB, H1 2017

Peritoneal Cancer – Pipeline by Mabion SA, H1 2017

Peritoneal Cancer – Pipeline by MabVax Therapeutics Holdings Inc, H1 2017

Peritoneal Cancer – Pipeline by Mateon Therapeutics Inc, H1 2017

Peritoneal Cancer – Pipeline by MedImmune LLC, H1 2017

Peritoneal Cancer – Pipeline by Medivir AB, H1 2017

Peritoneal Cancer – Pipeline by Merck & Co Inc, H1 2017

Peritoneal Cancer – Pipeline by Merck KGaA, H1 2017

Peritoneal Cancer – Pipeline by Millennium Pharmaceuticals Inc, H1 2017

Peritoneal Cancer – Pipeline by MolMed SpA, H1 2017

Peritoneal Cancer – Pipeline by Mycenax Biotech Inc, H1 2017

Peritoneal Cancer – Pipeline by NewLink Genetics Corp, H1 2017

Peritoneal Cancer – Pipeline by Novartis AG, H1 2017

Peritoneal Cancer – Pipeline by Novogen Ltd, H1 2017

Peritoneal Cancer – Pipeline by Oasmia Pharmaceutical AB, H1 2017

Peritoneal Cancer – Pipeline by OBI Pharma Inc, H1 2017

Peritoneal Cancer – Pipeline by Oncobiologics Inc, H1 2017

Peritoneal Cancer – Pipeline by Oncolix Inc, H1 2017

Peritoneal Cancer – Pipeline by Oncolytics Biotech Inc, H1 2017

Peritoneal Cancer – Pipeline by OncoMed Pharmaceuticals Inc, H1 2017

Peritoneal Cancer – Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Peritoneal Cancer – Pipeline by Oxford BioMedica Plc, H1 2017

Peritoneal Cancer – Pipeline by Pfizer Inc, H1 2017

Peritoneal Cancer – Pipeline by Pharma Mar SA, H1 2017

Peritoneal Cancer – Pipeline by Polaris Pharmaceuticals Inc, H1 2017

Peritoneal Cancer – Pipeline by PsiOxus Therapeutics Ltd, H1 2017

Peritoneal Cancer – Pipeline by Richter Gedeon Nyrt, H1 2017

Peritoneal Cancer – Pipeline by Samyang Holdings Corp, H1 2017

Peritoneal Cancer – Pipeline by Sanofi, H1 2017

Peritoneal Cancer – Pipeline by Sanofi Pasteur SA, H1 2017

Peritoneal Cancer – Pipeline by Sotio AS, H1 2017

Peritoneal Cancer – Pipeline by Syndax Pharmaceuticals Inc, H1 2017

Peritoneal Cancer – Pipeline by TapImmune Inc, H1 2017

Peritoneal Cancer – Pipeline by Tyrogenex Inc, H1 2017

Peritoneal Cancer – Pipeline by Vascular Biogenics Ltd, H1 2017

Peritoneal Cancer – Pipeline by VentiRx Pharmaceuticals Inc, H1 2017

Peritoneal Cancer – Pipeline by Verastem Inc, H1 2017

Peritoneal Cancer – Dormant Projects, H1 2017

Peritoneal Cancer – Dormant Projects, H1 2017 (Contd..1), H1 2017

Peritoneal Cancer – Dormant Projects, H1 2017 (Contd..2), H1 2017

Peritoneal Cancer – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Peritoneal Cancer, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports